Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
inflammation
Biotech
TScan’s strategy unaffected by Amgen scrapping $500M+ collab
“There are no planned changes to our wholly owned programs as a result of the Amgen collaboration being terminated,” TScan told Fierce.
Darren Incorvaia
Aug 19, 2026 5:31pm
Regeneron ends eye disease trial following safety review
Aug 17, 2026 2:30pm
Attovia's CEO aims to scratch itch opportunity with $289M IPO
Aug 5, 2026 7:00am
Avere goes public via reverse merger, pays $120M for Hansoh drug
Jul 14, 2026 6:00am
Spero pivots to I&I via $1.1B deal with Innovent antibody
Jul 14, 2026 6:00am
Bionyra emerges with $165M and three licensed I&I assets
Jun 22, 2026 7:00am
